ARTICLE | Clinical News
Firmagon degarelix regulatory update
April 21, 2014 7:00 AM UTC
The U.K.'s NICE issued a final appraisal determination (FAD) recommending Ferring's Firmagon degarelix to treat advanced hormone-dependent prostate cancer only in a subgroup of patients with spinal metastases who present signs or symptoms of spinal cord compression. The gonadotropin-releasing hormone (GnRH) antagonist is approved in the EU to treat advanced hormone-dependent prostate cancer. The FAD is in line with draft guidance issued in December (see BioCentury, Jan. 6). ...